The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically been dominated by chemotherapies. Keytruda (Merck) and Tecentriq (Roche / Genentech) have since been approved for previously untreated patients, with Keytruda gaining quick FDA approval in the non-muscle-invasive, BCG-unresponsive population as immune checkpoint inhibitors have spread across different stages of disease. Biomarker-driven treatments are becoming increasingly attractive, highlighted by Balversa’s FDA approval in April 2019. Furthermore, the entrance of Padcev in the third-line setting in the United States provides patients with an extra treatment option for metastatic disease. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for both muscle-invasive and non-muscle-invasive bladder cancer within the forecast period.
- What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer populations, and how will drug-treatment rates change over time?
- How is bladder cancer currently treated, and what are the (dis)advantages of existing drugs? What is the expected market impact of recent approvals?
- Which of the emerging therapies seem most promising, and what sales/uptake could they secure in the bladder cancer market?
- What are the drivers and constraints in the bladder cancer market, and how will the market evolve over the 10-year forecast period?
Geographies: United States, EU5, Japan.
Primary Research: 20 country-specific interviews with thought-leading urologists and medical oncologists. Supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed and recurrent incidence of bladder cancer by country, segmented by clinically and commercially relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient share of key bladder cancer therapies through 2028, segmented by brands / generics and epidemiological subpopulations.
Emerging Therapies: Phase III/PR: 13 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.